参考文献/References:
[1] 许晓龙. 冠心病微循环障碍的临床研究[J]. 中西医结合心血管病电子杂志,2019,7(34): 105.
[2] 张娟,薛一涛. 冠脉微循环障碍的中医治疗研究进展[J/OL]. 辽宁中医药大学学报: 1-7[2021-01-05]. http:// kns.cnki.net/kcms/detail/21.1543.R.20201011.1125.002.html.
[3] 邵建华,叶红. 血液流变学与活血化瘀疗法原理[J]. 数理医药学杂志,2010,23(6): 720-721.
[4] Vancheri F, Longo G, Vancheri S, et al. Coronary microvascular dysfunction[J]. Journal of Clinical Medicine, 2020, 9(9): 2880.
[5] Shome J S, Perera D, Plein S, et al. Current perspectives in coronary microvascular dysfunction[J]. Microcirculation. 2017, 24(1): 10, 1111.
[6] Yang H M, Yoon M H, Lim H S, et al. Lipid-core plaque assessed by near-infrared spectroscopy and procedure related microvascular injury[J]. Korean Circulation Journal, 2019, 49(11): 1010-1018.
[7] Heusch G, Skyschally A, Kleinbongard P. Coronary microembolization and microvascular dysfunction[J]. International Journal of Cardiology, 2018, 258: 17-23.
[8] Lin J, Zhang L, Zhang M, et al. Mst1 inhibits CMECs autophagy and participates in the development of diabetic coronary microvascular dysfunction[J]. Scientific Reports, 2016, 6: 34199.
[9] Aikawa K, Saitoh S, Muto M, et al. Effects of antioxidants on coronary microvascular spasm induced by epicardial coronary artery endothelial injury in pigs[J]. Coronary Artery Disease, 2004, 15(1): 21-30.
[10] Schroder J, Mygind N D, Frestad D, et al. Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction[J]. IJC Heart and Vasculature . 2019, 24: 100370.
[11] 王岚峰,修春红,李丹,等. 急性心肌梗死后心肌微循环障碍与炎症反应的关系[J]. 中华超声影像学杂志,2008(8): 672-674.
[12] Lerman A, Holmes D R, Herrmann J, et al. Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both? The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology[J]. European Heart Journal, 2007, 28(7): 788-797.
[13] 陈金香,钱菊英. 冠状动脉微循环功能的定量评估技术及进展[J]. 中国临床医学,2020,27(6): 1052-1056.
[14] Beyer A M, Gutterman D D. Regulation of the human coronary microcirculation[J]. Journal of Molecular and Cellular Cardiology, 2012, 52: 814-821.
[15] Murai T, Lee T, Kanaji Y, et al. The influence of elective percutaneous coronary intervention on microvascular resistance: a serial assessment using the index of microcirculatory resistance[J]. American Journal of Physiology-Heart and Circulatory, 2016, 311(3): H520-531.
[16] Fearon W F, Kobayashi Y. Invasive assessment of the coronary microvasculature: the index of microcirculatory resistance[J]. Circulation: Cardiovascular Interventions, 2017, 10(12): e005361.
[17] Pijls N H J, Fearon W F, Tonino P A L, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study[J]. Journal of the American College of Cardiology, 2010, 56: 177-184.
[18] Levine G N, Bates E R, Blankenship J C, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions[J]. Journal of the American College of Cardiology, 2011, 58(24): e44-e122.
[19] Kolh P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization:the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. European Heart Journal, 2014, 35(37): 2541-2619.
[20] Pijls N H, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsigni?cant stenosis: 5-year follow-up of the DEFER study[J]. Journal of the American College of Cardiology, 2007, 49(21): 2105-2111.
[21] 于睿,兰宇. “以络论治”心肌微循环障碍[J]. 中华中医药学刊,2008(4): 828-829.
[22] 王梦娟,范宗静,谢连娣. 从络脉失和论治微血管性心绞痛[J]. 辽宁中医杂志,2020,47(2): 78-80.
[23] 冯宇. 心之络病—孙络瘀阻的中医微观病理特征研究[D]. 北京: 中国人民解放军医学院,2019.
[24] 张辰浩,刘冠男,孔晓琳,等. 801例冠心病患者PCI术后中医证候及相关因素的回顾性研究[J]. 中医杂志,2018,59(20): 1766-1770.
[25] 李彬,毕颖斐,赵志强,等. PCI与CABG术后中医证候特征的专家调查[J]. 天津中医药,2013,30(8): 503-505.
[26] 万蝉俊,毛静远,王贤良,等. 理气宽胸活血法治疗心脏X综合征回顾性队列研究[J]. 北京中医药,2012,31(3): 175-178.
[27] 郭晓丽. 理气宽胸活血方联合法舒地尔治疗心脏X综合征疗效及对患者心肌微循环、血管内皮细胞功能的影响[J]. 陕西中医,2019,40(4): 459-461.
[28] 张玉芬,王玉珍,赵洁,等. 补肾活血汤对去卵巢大鼠心脏微血管内皮细胞形态及血清E_2、ET、NO、PGI_2、TXA_2含量的影响[J]. 现代生物医学进展,2014,14(31): 6044-6049,6038.
[29] 周朝辉,任怡. 益气活血化痰通络方对冠心病PCI术后患者中医症侯积分及生活质量的影响[J]. 四川中医,2020,38(11): 98-101.
[30] 谭勇文. 益气化痰活血法对PCI术后心肌保护的临床研究[D]. 广州: 广州中医药大学,2011.
[31] 黄宇,赵汉君,王肖龙. 益气活血化痰方改善急性冠脉综合征冠状动脉介入术中慢血流/无复流的作用机制[J].中西医结合心脑血管病杂志,2020,18(16): 2614-2618.
[32] 张新军,朱建红. 活血宁心汤对急性心肌梗死再灌注后心肌微循环的影响[J]. 四川中医,2016,34(7): 69-70.
[33] 贾承明. 心肌M1/M2极化在小鼠去卵巢CMD中的作用及补肾活血方的影响[D]. 西安: 第四军医大学,2017.
[34] 张萌,李明,张莉,等. 补肾活血软坚方对大鼠冠脉微血管病变内皮损伤相关因子NO、ET-1的影响[J]. 泰山医学院学报,2020,41(10): 728-731.
[35] 李英争. 麝香保心丸治疗冠脉介入后微循环障碍的效果及对心功能的影响分析[J]. 中国现代药物应用,2020,14(17): 138-139.
[36] 薛增明,李雅超,杨彦立,等. 麝香保心丸联合尼可地尔对心肌梗死后冠脉微循环障碍患者心脏功能和血流动力学水平的影响[J]. 中国煤炭工业医学杂志,2020,23(1): 70-74.
[37] 薛增明,李雅超,杨彦立,等. 麝香保心丸联合尼可地尔对心绞痛后冠脉微循环障碍患者的疗效及一氧化氮、血管紧张素Ⅱ、内皮素-1、C-反应蛋白的变化研究[J]. 辽宁中医杂志,2020,47(6): 112-114.
[38] 李磊. 冠脉微循环障碍模型的建立及双参宁心胶囊的干预作用研究[D]. 北京: 中国中医科学院,2019.
[39] 李雪丽,刘建勋,郭宇洁. 双参宁心方对大鼠心肌缺血/再灌注损伤能量代谢的影响[J]. 中国中药杂志,2013,38(17): 2874-2877.
[40] 董竞方,马晓昌. 双参宁心颗粒治疗气虚血瘀型稳定型心绞痛疗效观察[J]. 西部中医药,2019,32(1): 70-73.
[41] 刘国清,徐丹苹,李育楷,等. 冠脉CTA评估参术冠心颗粒干预冠状动脉斑块和心肌微循环疗效研究[J]. 广州中医药大学学报,2019,36(6): 776-782.
[42] 徐丹苹,吴焕林. 参术冠心颗粒对心肌梗死大鼠冠脉微循环的影响[J]. 中国病理生理杂志,2014,30(3): 438-443.
[43] 方燕,郑旭旭,李丽燕. 大蒜素预处理对急性心肌梗死模型大鼠心肌病理改变的影响[J]. 浙江中西医结合杂志,2020,30(12): 9-10,957-962.
[44] 张正升,韩贵芝,张丹丹,等. 大蒜素对心肌缺血大鼠心肌组织CGRP及其受体mRNA表达水平的影响[J]. 中西医结合心脑血管病杂志,2020,18(10): 1543-1546.
[45] 谷万里. 大蒜素对寒凝血瘀心肌缺血气体信号分子调控及微循环影响的研究[D]. 北京: 北京中医药大学,2007.
[46] 丰冠鹏,魏运亮,白雁,等. STEMI患者PCI术中冠状动脉注射三七总皂甙的临床效果[J]. 实用医药杂志,2017,34(2): 143-145.
[47] 马军. 三七总皂苷改善急性心肌梗死PCI术后心肌缺血再灌注损伤的临床研究[D]. 武汉: 湖北中医药大学,2018.